Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab for High-frequent Aflibercept Treated nAMD (FAN)
NCT05941715Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- Jul 2023
- Primary completion
- Sep 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of faricimab in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Medical University of Graz. Primary endpoint: Proportion of eyes with at least one extension without retinal fluid at 32 weeks. Started Jul 2023; status: completed.
02
Drugs
faricimab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05941715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05941715.